We bring you the latest news from the healthcare about the health care in the United Kingdom. Do your have news for us? Contact the editor. Watch also this special movie.

dinsdag 22 augustus 2017

The Lancet: [News] Ready-to-use T cells for infection after stem-cell transplant

[News] Ready-to-use T cells for infection after stem-cell transplant
A new phase 2 trial suggests that cryopreserved virus-specific T cells (VSTs) prepared from third-party donors are a safe and effective treatment for recipients of allogeneic hematopoietic stem cell transplantation (allo-HSCT) who develop drug-refractory viral infections. Viral infection is a common, life-threatening complication for these patients, and drug treatment can be ineffective or have substantial side-effects.
Read more

[News] Genetic basis for response to cancer immunotherapy
A new study has identified dozens of new genes that might affect a patient's response to cancer immunotherapy.
Read more

[Articles] Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
HRQOL was maintained for patients with advanced, non-functional, gastrointestinal or lung NETs, with no relevant differences noted between the everolimus and placebo groups. In view of the previous RADIANT-4 findings of longer progression-free survival with everolimus, our findings suggest that everolimus delays disease progression while preserving overall HRQOL, even with the usual toxic effects related to active targeted drug treatment for cancer.
Read more

[Comment] Maintaining quality of life for patients with neuroendocrine tumours
Ideally, new treatments should either improve overall survival or the health-related quality of life (HRQOL) of patients, or both, and should have a favourable cost-to-benefit ratio. For instance, FOLFIRINOX (leucovorin, fluorouracil, irinotecan, and oxaliplatin) significantly improves progression-free survival, overall survival, and HRQOL compared with gemcitabine in patients with metastatic pancreatic adenocarcinoma, even though it causes substantially more side-effects.1,2 After publication of the RADIANT-3 and RADIANT-4 randomised, placebo-controlled, phase 3 studies, everolimus was approved for all non-functional, advanced, neuroendocrine tumours (NETs), including those of the pancreas,3 lung, and gastrointestinal tract,4 and sunitinib has been approved for pancreatic NETs (pNETs).
Read more

[Articles] Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial
Rindopepimut did not increase survival in patients with newly diagnosed glioblastoma. Combination approaches potentially including rindopepimut might be required to show efficacy of immunotherapy in glioblastoma.
Read more